"This morning, Kimberly-Clark, the personal care corporation behind brands like Kleenex, Huggies, and Cottonelle, announced that it's struck an agreement to acquire Kenvue (which, alongside Tylenol, also owns brands like Band-Aid, Zyrtec, and Listerine). The deal, which is expected to close in the second half of 2026, will proceed through a cash and stock transaction that's set to value Kenvue at around $48.7 billion. Kenvue stock was up as much as 19% in premarket trading."
"On the morning of September 22, shares of the company dropped around 7.5% as shareholders caught wind of President Trump's plans to publicly claim that Tylenol consumption could be linked to autism. Later that afternoon, Trump did just that at a White House conference where he instructed pregnant women, around a dozen times, "Don't take Tylenol." The claim that Tylenol use is connected to autism has been widely debunked by experts and is not backed by medical science."
Kimberly‑Clark agreed to acquire Kenvue in a cash-and-stock transaction valuing Kenvue at about $48.7 billion, with the deal expected to close in the second half of 2026. Kenvue's portfolio includes Tylenol, Band-Aid, Zyrtec, and Listerine; Kimberly‑Clark owns Kleenex, Huggies, and Cottonelle. Kenvue shares jumped in premarket trading while Kimberly‑Clark shares fell. Kenvue recently faced reputational pressure after President Trump publicly asserted an unproven link between Tylenol and autism; experts have widely debunked that claim. Kenvue disputed any connection between Tylenol and autism, and the acquisition appears to have reassured investors.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]